CERo Therapeutics (CERO) Competitors $5.28 -0.11 (-2.04%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$5.32 +0.04 (+0.76%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERO vs. LEXX, ALLR, HOTH, RLYB, MIRA, ENLV, MTVA, LIXT, SNYR, and PASGShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Lexaria Bioscience (LEXX), Allarity Therapeutics (ALLR), Hoth Therapeutics (HOTH), Rallybio (RLYB), MIRA Pharmaceuticals (MIRA), Enlivex Therapeutics (ENLV), MetaVia (MTVA), Lixte Biotechnology (LIXT), Synergy CHC (SNYR), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. Its Competitors Lexaria Bioscience Allarity Therapeutics Hoth Therapeutics Rallybio MIRA Pharmaceuticals Enlivex Therapeutics MetaVia Lixte Biotechnology Synergy CHC Passage Bio Lexaria Bioscience (NASDAQ:LEXX) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk. Which has more volatility & risk, LEXX or CERO? Lexaria Bioscience has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Which has better earnings and valuation, LEXX or CERO? Lexaria Bioscience has higher revenue and earnings than CERo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$460K37.37-$5.80M-$0.67-1.31CERo TherapeuticsN/AN/A-$8.30MN/AN/A Does the media prefer LEXX or CERO? In the previous week, Lexaria Bioscience and Lexaria Bioscience both had 1 articles in the media. Lexaria Bioscience's average media sentiment score of 0.00 beat CERo Therapeutics' score of -1.00 indicating that Lexaria Bioscience is being referred to more favorably in the media. Company Overall Sentiment Lexaria Bioscience Neutral CERo Therapeutics Negative Do analysts prefer LEXX or CERO? Lexaria Bioscience currently has a consensus target price of $4.00, indicating a potential upside of 355.17%. CERo Therapeutics has a consensus target price of $45.00, indicating a potential upside of 752.27%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00CERo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Do insiders & institutionals believe in LEXX or CERO? 13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 26.4% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 12.7% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is LEXX or CERO more profitable? CERo Therapeutics has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. CERo Therapeutics' return on equity of 0.00% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,849.19% -157.22% -133.69% CERo Therapeutics N/A N/A -209.40% SummaryCERo Therapeutics beats Lexaria Bioscience on 7 of the 13 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.36M$2.61B$6.12B$10.58BDividend YieldN/A52.87%5.65%4.69%P/E RatioN/A24.2286.9626.71Price / SalesN/A724.90605.88130.98Price / CashN/A172.1237.9061.31Price / Book-0.135.3412.556.55Net Income-$8.30M$32.92M$3.31B$277.50M7 Day Performance-2.04%3.90%4.28%2.42%1 Month Performance-10.81%8.79%6.90%8.63%1 Year Performance-97.17%-3.79%70.54%31.60% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo Therapeutics2.6492 of 5 stars$5.28-2.0%$45.00+752.3%-97.2%$6.36MN/A0.008Negative NewsShort Interest ↑LEXXLexaria Bioscience2.6052 of 5 stars$1.31-3.0%$4.00+205.3%-72.5%$26.41M$460K-1.967ALLRAllarity Therapeutics2.9855 of 5 stars$1.60-10.1%$9.00+462.5%-11.9%$26.02MN/A0.0010Short Interest ↓HOTHHoth Therapeutics1.7602 of 5 stars$2.07+6.7%$4.00+93.2%+91.3%$25.72MN/A-1.934Short Interest ↑Gap UpRLYBRallybio3.48 of 5 stars$0.59-3.8%$5.00+753.1%-49.1%$25.45M$761K-0.6240News CoverageAnalyst UpgradeShort Interest ↓Gap UpMIRAMIRA Pharmaceuticals0.5466 of 5 stars$1.30-2.3%$17.00+1,207.7%+17.4%$25.36MN/A-2.652Analyst UpgradeENLVEnlivex Therapeutics2.7483 of 5 stars$1.05-0.5%$10.00+852.4%-33.3%$24.96MN/A-1.8170MTVAMetaVia2.3834 of 5 stars$1.03flat$7.50+628.2%N/A$24.92MN/A0.008LIXTLixte Biotechnology0.3027 of 5 stars$5.22-3.7%N/A+187.6%$24.72MN/A-4.054Short Interest ↑Gap UpSNYRSynergy CHC3.8795 of 5 stars$2.70+5.5%$10.00+270.4%-37.5%$24.17M$34.83M7.1140PASGPassage Bio3.335 of 5 stars$7.53-0.1%$75.67+904.9%-38.8%$23.97MN/A-0.41130 Related Companies and Tools Related Companies LEXX Alternatives ALLR Alternatives HOTH Alternatives RLYB Alternatives MIRA Alternatives ENLV Alternatives MTVA Alternatives LIXT Alternatives SNYR Alternatives PASG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERO) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
